32 Biotechnology Stocks to Sell Now

32 Biotechnology Stocks to Sell Now

The ratings of 32 Biotechnology stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Slipping from a C to a D rating, Incyte Corporation (INCY) takes a hit this week. Incyte Corporation is using its expertise in genomics and medicinal chemistry, as well as molecular, cellular, and in vivo biology to discover and develop novel therapeutics. For more information, get Portfolio Grader’s complete analysis of INCY stock.

This week, bluebird bio, Inc.’s (BLUE) rating worsens to a F from the company’s D rating a week ago. The company also gets F’s in sales growth and return on equity. For more information, get Portfolio Grader’s complete analysis of BLUE stock.

Prothena Corp. Plc (PRTA) gets weaker ratings this week as last week’s C drops to a D. The company also gets F’s in earnings revisions, earnings surprise, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of PRTA stock.

ACADIA Pharmaceuticals Inc. (ACAD) experiences a ratings drop this week, going from last week’s C to a D. ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company also gets F’s in earnings revisions, earnings surprise, and return on equity. For more information, get Portfolio Grader’s complete analysis of ACAD stock.

This week, Cellectis SA Sponsored ADR (CLLS) drops from a C to a D rating. The company also gets F’s in operating margin growth, earnings revisions, and earnings surprise. For more information, get Portfolio Grader’s complete analysis of CLLS stock.

Genomic Health, Inc. (GHDX) declines this week from a C to a D. Genomic Health, Inc. is a life science company, which is focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of GHDX stock.

This is a rough week for Acorda Therapeutics, Inc. (ACOR). The company’s rating falls to F from the previous week’s D. Acorda Therapeutics, Inc. is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. The company also gets F’s in operating margin growth, earnings growth, earnings revisions, and earnings surprise. For more information, get Portfolio Grader’s complete analysis of ACOR stock.

Foundation Medicine, Inc. (FMI) is having a tough week. The company’s rating falls from a B to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of FMI stock.

Heron Therapeutics Inc’s (HRTX) rating weakens this week, dropping to a F versus last week’s D. The company also gets F’s in earnings revisions, earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of HRTX stock.

Global Blood Therapeutics Inc (GBT) earns a F this week, moving down from last week’s grade of D. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of GBT stock.

FibroGen, Inc. (FGEN) slips from a D to a F this week. The company also gets F’s in sales growth, earnings revisions, and return on equity. For more information, get Portfolio Grader’s complete analysis of FGEN stock.

Flexion Therapeutics, Inc. (FLXN) gets weaker ratings this week as last week’s C drops to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of FLXN stock.

Insys Therapeutics, Inc. (INSY) declines this week from a D to a F. Insys Therapeutics, Inc. develops pharmaceutical products that target the unmet needs of cancer patients, with a focus on cancer-supportive care. The company also gets F’s in sales growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of INSY stock.

This is a rough week for Aduro BioTech, Inc. (ADRO). The company’s rating falls to D from the previous week’s C. For more information, get Portfolio Grader’s complete analysis of ADRO stock.

Slipping from a C to a D rating, Applied Genetic Technologies Corp. (AGTC) takes a hit this week. For more information, get Portfolio Grader’s complete analysis of AGTC stock.

This week, Natera, Inc.’s (NTRA) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of NTRA stock.

Halozyme Therapeutics, Inc. (HALO) is having a tough week. The company’s rating falls from a D to a F. Halozyme Therapeutics, Inc. is a biopharmaceutical company developing products for the diabetes, cancer, dermatology and drug delivery markets. The company also gets F’s in sales growth, earnings growth, and return on equity. For more information, get Portfolio Grader’s complete analysis of HALO stock.

Enzymotec Ltd. (ENZY) slips from a C to a D this week. The company also gets F’s in sales growth, earnings growth, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of ENZY stock.

Epizyme, Inc.’s (EPZM) rating weakens this week, dropping to a F versus last week’s D. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of EPZM stock.

Pfenex, Inc. (PFNX) earns a F this week, moving down from last week’s grade of D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of PFNX stock.

Invitae Corp. (NVTA) experiences a ratings drop this week, going from last week’s B to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of NVTA stock.

This week, Progenics Pharmaceuticals, Inc. (PGNX) drops from a C to a D rating. Progenics Pharmaceuticals, Inc. develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. The company also gets F’s in operating margin growth and return on equity. For more information, get Portfolio Grader’s complete analysis of PGNX stock.

Slipping from a C to a D rating, Agenus Inc. (AGEN) takes a hit this week. Agenus Inc. is a biotechnology company that engages in developing and commercializing technologies to treat cancers and infectious diseases. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of AGEN stock.

Spectrum Pharmaceuticals, Inc. (SPPI) experiences a ratings drop this week, going from last week’s D to a F. Spectrum Pharmaceuticals, Inc. is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology. The company also gets F’s in sales growth, earnings surprise, and return on equity. For more information, get Portfolio Grader’s complete analysis of SPPI stock.

This week, Mirati Therapeutics Inc.’s (MRTX) rating worsens to a F from the company’s D rating a week ago. Mirati Therapeutics Inc. engages in the development of therapeutics for the treatment of cancer. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of MRTX stock.

Keryx Biopharmaceuticals, Inc. (KERX) earns a D this week, moving down from last week’s grade of C. Keryx Biopharmaceuticals, Inc. focuses on developing and commercializing pharmaceuticals for the treatment of cancer and renal disease. The company also gets F’s in earnings revisions, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of KERX stock.

Regulus Therapeutics Inc.’s (RGLS) rating weakens this week, dropping to a F versus last week’s D. Regulus Therapeutics Inc. focuses on the discovery and development of drugs that target microRNAs to treat various diseases in the United States. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of RGLS stock.

Aurinia Pharmaceuticals Inc. (AUPH) slips from a B to a D this week. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of AUPH stock.

Conatus Pharmaceuticals Inc. (CNAT) gets weaker ratings this week as last week’s D drops to a F. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of CNAT stock.

This week, Synthetic Biologics, Inc. (SYN) drops from a C to a D rating. Synthetic Biologics, Inc. is a biotechnology company focused on the development of synthetic DNA-based therapeutics and innovative disease-modifying medicines for serious illnesses. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of SYN stock.

Catalyst Biosciences, Inc. (CBIO) is having a tough week. The company’s rating falls from a D to a F. The company also gets F’s in sales growth, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CBIO stock.

Cerulean Pharma, Inc. (CERU) declines this week from a C to a D. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of CERU stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/09/32-biotechnology-stocks-to-sell-now/.

©2019 InvestorPlace Media, LLC